Abstract 1780P
Background
In the backdrop of keener scrutiny of health equity issues, the impact of a new intervention on inequality in health outcomes is increasingly viewed as an element in health technology assessment. Non-Hispanic (NH) Black patients are disproportionally affected by non-metastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is an approved treatment for nmCRPC and was shown to be effective and safe among NH-Black patients in the ARAMIS trial. The objective of this study was to quantify the health inequality impact of darolutamide+ androgen-deprivation therapy (ADT) relative to ADT for nmCRPC in the U.S. by means of a distributional cost-effectiveness analysis.
Methods
With a decision model, the quality-adjusted life years (QALYs) and costs were estimated for NH-White, NH-Black, Asian, and Hispanic patients. The degree of differences in QALYs among these subgroups was expressed with Atkinson relative inequality indices (0 = equal outcomes and 1 = maximum inequality between subgroups) for both strategies. Their difference was defined as the inequality impact of darolutamide among treated patients. Subtracting equally distributed health opportunity costs from the QALY gains with darolutamide facilitated calculation of the overall health inequality impact across population subgroups.
Results
Darolutamide+ADT resulted in an additional 1.04 (95% confidence interval 0.57; 1.49) QALYs per treated patient relative to ADT, with the greatest gain observed among NH-Black patients (1.48 QALYs (0.49; 2.72)). The relative inequality in QALYs among patients reduced by 66%, from an inequality score of 0.032 (0.004; 0.080) with ADT to 0.011 (0.000; 0.049) with darolutamide+ADT. Factoring in health opportunity costs, treatment of eligible nmCRPC patients with darolutamide resulted in the largest net gain in QALYs among the NH-Black population, thereby having a favorable impact on inequalities in quality adjusted life expectancy.
Conclusions
Darolutamide+ADT for the treatment of nmCRPC results in greater health outcomes than ADT, and reduces inequality in health outcomes across subgroups according to race and ethnicity in the U.S.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bayer Pharmaceuticals.
Disclosure
J. Janssen, T. Flottemesch, I. Brewer, P. Sullivan: Financial Interests, Institutional, Full or part-time Employment, Precision heor was hired by Bayer to perform the research: PRECISIONheor. J. Partridge: Financial Interests, Personal, Full or part-time Employment, Full time employee of Bayer: Bayer Pharmaceuticals.
Resources from the same session
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14